GlaxoSmithKline plc Revenue 2011-2026 | GSK

Company revenue is the total amount of money received from the sale of goods or services over a certain period of time. It is one of the key indicators of a company's financial condition and success.

Traditionally defined as follows:
Revenue = Price * Quantity of products

Revenue is one of the components of a company’s income. In international practice, revenue is understood as the inflow or other increase in a company's assets or the settlement of its obligations that occurs as a result of the company’s core or main activity.^[1]

This is an important indicator for assessing the financial condition and efficiency of a company. It makes it possible to determine how successfully a company sells its products or services on the market. In addition, revenue can be used to calculate other financial indicators such as profit, profitability, and market share.

Various factors can influence this indicator, including demand for goods or services, market competition, economic conditions, and the company's marketing efforts. Therefore, its analysis and monitoring are important tasks for the successful development of a business.

Annual Revenue GlaxoSmithKline plc

2025	2024	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013	2012	2011
32.7 B	31.4 B	30.3 B	29.3 B	24.7 B	24.4 B	33.8 B	30.8 B	30.2 B	27.9 B	23.9 B	23 B	26.5 B	26.4 B	27.4 B

All numbers in GBP currency

Indicator range from annual reports

Maximum	Minimum	Average
33.8 B	23 B	28.2 B

References

Adhikari, B. (2010). Impact of Revenue Planning In Nepal Investment Bank Limited (Doctoral dissertation, Faculty of Management).

Revenue of other stocks in the Biotechnology industry

Issuer	Revenue	Price	% 24h	Market Cap	Country
MorphoSys AG MOR	238 M	-	2.43 %	$ 254 M	Germany
BioNTech SE BNTX	482 M	$ 95.5	-3.88 %	$ 27.2 B	Germany
AgeX Therapeutics AGE	130 K	-	-10.17 %	$ 12.2 K	USA
I-Mab IMAB	88 M	-	-	$ 866 M	China
Midatech Pharma plc MTP	381 K	-	-18.52 %	$ 27.3 M	Britain
Alexion Pharmaceuticals, Inc. ALXN	6.07 B	-	-	$ 40.3 B	USA
Genfit SA GNFT	70.9 M	-	2.54 %	$ 160 B	France
EyeGate Pharmaceuticals, Inc. EYEG	12.1 K	-	-1.52 %	$ 24.7 M	USA
Институт стволовых клеток человека ISKJ	1.08 B	-	-	-	Russia
ACADIA Pharmaceuticals ACAD	958 M	$ 22.35	0.72 %	$ 3.7 B	USA
Galapagos NV GLPG	1.11 B	$ 28.39	-0.13 %	$ 2.69 B	Belgium
Grifols, S.A. GRFS	7.21 B	$ 8.27	0.49 %	$ 6.83 B	Spain
Advaxis ADXS	13 K	-	-9.65 %	$ 45.9 M	USA
Can-Fite BioPharma Ltd. CANF	853 K	$ 3.5	5.42 %	$ 5.76 M	Israel
Aeterna Zentaris AEZS	7.5 M	-	5.93 %	$ 314 M	Canada
Aeglea BioTherapeutics AGLE	886 K	-	-	$ 1.01 B	USA
CureVac N.V. CVAC	48.9 M	-	-	$ 867 M	Germany
Applied Genetic Technologies Corporation AGTC	325 K	-	-	$ 26.5 M	USA
AIkido Pharma AIKI	123 M	-	1.93 %	$ 17.4 M	USA
InflaRx N.V. IFRX	29.3 K	$ 1.97	-7.51 %	$ 152 M	Germany
Aptinyx APTX	1 M	-	-39.0 %	$ 4.57 M	USA
Albireo Pharma ALBO	40.6 M	-	-0.23 %	$ 916 M	USA
AlloVir ALVR	165 K	-	4.14 %	$ 49.1 M	USA
Arcutis Biotherapeutics ARQT	376 M	$ 23.42	-0.3 %	$ 2.98 B	USA
Ampio Pharmaceuticals AMPE	1.16 M	-	-11.43 %	$ 502 K	USA
Alpine Immune Sciences ALPN	30.1 M	-	-	$ 2.17 B	USA
Applied Therapeutics APLT	9.99 M	-	-	$ 8.42 M	USA
Aravive ARAV	9.14 M	-	-13.39 %	$ 1.45 M	USA
Aridis Pharmaceuticals ARDS	3.09 M	-	17.91 %	$ 11.1 M	USA
Innate Pharma S.A. IPHA	9 M	$ 1.4	-2.1 %	$ 235 M	France
CRISPR Therapeutics AG CRSP	3.51 M	$ 52.38	-2.24 %	$ 4.71 B	Schweiz
Avenue Therapeutics ATXI	1.4 M	-	-52.27 %	$ 4.45 M	USA
Autolus Therapeutics plc AUTL	75.4 M	$ 1.64	4.46 %	$ 436 M	Britain
Inventiva S.A. IVA	9.2 M	$ 5.42	2.85 %	$ 138 M	France
Ayala Pharmaceuticals AYLA	692 K	-	-	$ 7.46 M	Israel
Завод ДИОД DIOD	517 M	-	-	-	Russia
Фармсинтез LIFE	372 M	-	-	-	Russia
AstraZeneca PLC AZN	58.7 B	-	-	$ 96.9 B	Britain